New anticancer strategies targeting HIF-1

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1061-1069

  Yeo, Eun Jin ^a   Chun, Yang Sook ^b   Park, Jong Wan ^a  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

ARNT; aryl hydrocarbon nuclear receptor translocator; basic helix loop helix; bHLH; Cancer; HIF; HRE; Hypoxia; hypoxia response element; hypoxia inducible factor; ODDD; oxygen dependent degradation domain; PAS; Per Arnt Sim; pVHL; von Hippel Lindau protein

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 METHOXYESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; GEFITINIB; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RADICICOL; RAPAMYCIN; RECOMBINANT DNA; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VINCRISTINE; VON HIPPEL LINDAU PROTEIN; WORTMANNIN;

CANCER CELL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; GENETICS; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOSIS; TOXICITY; TUMOR GROWTH; TUMOR PROMOTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE TARGETING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; NEOPLASMS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 4143050461     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.040     Document Type: Conference Paper

References (70)

1. Saijo N., Tamura T., Nishio K. Strategy for the development of novel anticancer drugs. Cancer Chemother. Pharmacol. 52:2003;S97-101
2. Elsayed Y.A., Sausville E.A. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 6:2001;517-537
3. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47
4. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8:2002;S62-67
5. Blancher C., Harris A.L. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev. 17:1998;187-194
6. Czyzyk-Krzeska M.F. Molecular aspects of oxygen sensing in physiological adaptation to hypoxia. Respir. Physiol. 110:1997;99-111
7. Bunn H.F., Poyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 76:1996;839-885
8. Semenza G.L., Agani F., Booth G., Forsythe J., Iyer N., Jiang B.H., et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 51:1997;553-555
9. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1995;1230-1237
10. Jiang B.H., Rue E., Wang G.L., Roe R., Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271:1996;17771-17778
11. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1 alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272:1997;19253-19260
12. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7987-7992
13. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340
14. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54
15. 2 sensing. Science. 292:2001;464-468
16. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472
17. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206
18. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10430-10435
19. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
20. Masson N., Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J. Cell Sci. 116:2003;3041-3049
21. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 111:2002;709-720
22. Tian H., McKnight S.L., Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:1997;72-82
23. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. U.S.A. 94:1997;4273-4278
24. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit. HIF3alpha. Gene Exp. 7:1998;205-213
25. Wiesener M.S., Turley H., Allen W.E., Willam C., Eckardt K.U., Talks K.L., et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood. 92:1998;2260-2268
26. Hara S., Hamada J., Kobayashi C., Kondo Y., Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem. Biophys. Res. Commun. 287:2001;808-813
27. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:1992;65-71
28. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8:2002;S62-67
29. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:2000;1541-1545
30. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:2001;3995-4004
31. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. Biol. Chem. 277:2002;27975-27981
32. Park J.H., Kim T.Y., Jong H.S., Kim T.Y., Chun Y.S., Park J.W., et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alpha in gastric cancer cells. Clin. Cancer Res. 9:2003;433-440
33. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835
34. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 88:2000;2606-2618
35. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:2000;4693-4696
36. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93:2001;309-314
37. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2001;2911-2916
38. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8104-8109
39. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015
40. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., Harris A.L. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 63:2003;6130-6134
41. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246
42. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF2alpha Is Sufficient to Suppress pVHL-defective tumor growth. PLoS Biol. 1:2003;439-444
43. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., Krissansen G.W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8:2001;638-645
44. Chun Y.S., Choi E., Yeo E.J., Lee J.H., Kim M.S., Park J.W. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J. Cell Sci. 114:2001;4051-4061
45. Chun Y.S., Choi E., Kim T.Y., Kim M.S., Park J.W. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem. J. 362:2002;71-79
46. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 414:2001;550-554
47. Makino Y., Kanopka A., Wilson W.J., Tanaka H., Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J. Biol. Chem. 277:2002;32405-32408
48. Minet E., Mottet D., Michel G., Roland I., Raes M., Remacle J., et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 460:1999;251-256
49. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277:2002;29936-29944
50. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:2002;2478-2482
51. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276:2001;9519-9525
52. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:1997;5328-5335
53. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
54. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:2003;391-396
55. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:2000;34-44
56. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277:2002;38205-38211
57. Stiehl D.P., Jelkmann W., Wenger R.H., Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 512:2002;157-162
58. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 3:2003;363-375
59. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62:2002;4316-4324
60. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood. 84:1994;4226-4233
61. Mulsch A., Bauersachs J., Schafer A., Stasch J.P., Kast R., Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 120:1997;681-689
62. Wegener J.W., Nawrath H. Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur. J. Pharmacol. 323:1997;89-91
63. Mizusawa H., Hedlund P., Brioni J.D., Sullivan J.P., Andersson K.E. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. 167:2002;2276-2281
64. Hsieh G.C., O'Neill A.B., Moreland R.B., Sullivan J.P., Brioni J.D. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur. J. Pharmacol. 458:2003;183-189
65. Lee Y.C., Martin E., Murad F. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10763-10768
66. Friebe A., Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 53:1998;123-127
67. Chun Y.S., Yeo E.J., Choi E., Teng C.M., Bae J.M., Kim M.S., et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 61:2001;947-954
68. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95:2003;516-525
69. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2:2003;803-811
70. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:2003;721-732